Fox Chase Cancer Center News

PHILADELPHIA (October 4, 2019) – Elizabeth Handorf, PhD, and her colleagues used net monetary benefit (NMB) to quantify cost effectiveness.

PHILADELPHIA (October 3, 2019) – No associations between location of the tumor and risk for death or tumor recurrence were found. These data do not change how patients with retroperitoneal sarcomas would be treated, but do provide clinicians with a better understanding of the disease.

PHILADELPHIA (October 2, 2019) – Gina Mantia-Smaldone, MD, has been selected by the Gynecological Oncology Group Foundation and NRG Oncology to receive three years of funding to develop her research capacity and scope as a principal investigator of gynecologic malignancies.

PHILADELPHIA (October 1, 2019) – October is Breast Cancer Awareness month.

PHILADELPHIA (September 27, 2019) – These results underscore the ability of a higher-volume facility to provide patients with more experience, expertise, and access to resources.

PHILADELPHIA (September 23, 2019) – Edna Cukierman, PhD, was awarded the grant from the National Institutes of Health/National Cancer Institute to begin research on better understanding the deterioration of collagen integrity via cellular aging and its role in melanoma metastasis.

PHILADELPHIA (September 23, 2019) – Of the 112 patients examined, 14 percent developed at least one cranial neuropathy. The median time was more than seven years, with some patients developing it more than 10 years later.

PHILADELPHIA (September 20, 2019) – Many of the most common treatment modalities for localized non-melanoma skin cancers resulted in similar cosmetic outcome and local control one year after treatment, according to a new study from researchers at Fox Chase Cancer Center.